You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA1030
  • Published:  15 January 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Declaration of interests
  2. Final draft guidance
  3. Draft guidance
  4. Invitation to participate

History

Documents created during the development process.

Declaration of interests

  • Register of interests (PDF 149 KB)

    Published:
    20 January 2025

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 245 KB)

    Published:
    06 December 2024
  • Committee papers (PDF 1.91 MB)

    Published:
    06 December 2024
  • Public committee slides (PDF 879 KB)

    Published:
    06 December 2024
  • Equality impact assessment (downloadable version) (PDF 137 KB)

    Published:
    06 December 2024

Draft guidance

  • Draft guidance

  • Draft consultation document (online commenting)

  • Draft consultation document (downloadable version) (PDF 317 KB)

    Published:
    30 July 2024
  • Committee papers (PDF 9.14 MB)

    Published:
    30 July 2024
  • Public committee slides (PDF 1.02 MB)

    Published:
    30 July 2024
  • Equality impact assessment (downloadable version) (PDF 147 KB)

    Published:
    30 July 2024

Invitation to participate

  • Invitation to participate

  • Final stakeholder list (PDF 170 KB)

    Published:
    21 November 2023
  • Equality impact assessment (Scoping) (PDF 126 KB)

    Published:
    21 November 2023
  • Final scope (PDF 284 KB)

    Published:
    30 November 2023
Back to top